ArticleInternational orthopaedics2026
Investigating the impact of Glucagon-like peptide-1 therapy on total shoulder arthroplasty outcomes.
Article in International orthopaedics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe increasing prevalence of Glucagon-like peptide-1 receptor agonists (GLP-1 RA) has raised concerns about their perioperative impact. Although database studies on GLP-1 RAs in total shoulder arthroplasty (TSA) have been published for diabetic and general TSA patients, results are conflicting, and the effects on patients across various obesity classes remain unexplored. This study aims to fill this gap.
methodsThe PearlDiver database was used to identify patients who underwent primary TSA, grouped by GLP-1 use, obesity status, and obesity class. Post-operative outcomes included 90-day readmission and emergency department (ED) visit rates, medical complications (including thromboembolic, infectious, and renal events), and orthopaedic complications (including revision, periprosthetic joint infection, and instability). Cohorts were matched 10:1 by exact matching on age, sex, Elixhauser comorbidity index, diabetes, hypertension and overall obesity status, and multivariable regression was used to adjust for comorbidities that remained imbalanced after matching.
resultsAmong 95,566 patients, 1,549 (1.62%) were GLP-1 users. Initially, GLP-1 users exhibited higher pre-operative comorbidity burdens and rates of complications. However, after matching and multivariable adjustment for residual imbalance, no significant differences in medical or orthopaedic outcomes persisted. Notably, GLP-1 users demonstrated significantly lower odds of 90-day ED visits (OR 0.75; P < .01) and readmissions (OR 0.71; P < .01). Similar trends were observed within each individual obesity class, but none reached statistical significance, most likely reflecting the small size of these subgroups.
conclusionAfter accounting for pre-operative comorbidities, our findings suggest that GLP-1 RA use is not associated with worse surgical outcomes in TSA patients and may be associated with lower post-operative healthcare utilisation, although residual confounding cannot be excluded. Further longitudinal studies are warranted to optimise perioperative GLP-1 RA administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.